Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2024-06-21 00:00:00 ET · period of report 2024-06-21 · accession 0001213900-24-054781 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-21 | 2024-06-21 | ORMP | Gabay Avraham | CFO | A - Grant | — | +140.0K | 0 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-21 | A | A | 140,040 | — | 0 | D | — | — | (F1) Represents a grant of 140,040 Restricted Stock Units ("RSUs"), of which 93,360 will vest on June 18, 2026 and the remaining 46,680 will vest in four equal quarterly installments of 11,670 starting September 18, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |